Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 9 (1), 16423

The Relationship of Circulating Fibroblast Growth Factor 21 Levels With Pericardial Fat: The Multi-Ethnic Study of Atherosclerosis

Affiliations

The Relationship of Circulating Fibroblast Growth Factor 21 Levels With Pericardial Fat: The Multi-Ethnic Study of Atherosclerosis

Arsenios Magdas et al. Sci Rep.

Abstract

Previous small studies have reported an association between circulating fibroblast growth factor 21 (FGF21) levels and pericardial fat volume in post-menopausal women and high cardiovascular disease (CVD) risk patients. In this study, we investigated the relationship of FGF21 levels with pericardial fat volume in participants free of clinical CVD at baseline. We analysed data from 5765 men and women from the Multi-Ethnic Study of Atherosclerosis (MESA) with both pericardial fat volume and plasma FGF21 levels measured at baseline. 4746 participants had pericardial fat volume measured in at least one follow-up exam. After adjusting for confounding factors, ln-transformed FGF21 levels were positively associated with pericardial fat volume at baseline (β = 0.055, p < 0.001). When assessing change in pericardial fat volume over a mean duration of 3.0 years using a linear mixed-effects model, higher baseline FGF21 levels were associated with higher pericardial fat volume at baseline (2.381 cm3 larger in pericardial fat volume per one SD increase in ln-transformed FGF21 levels), but less pericardial fat accumulation over time (0.191 cm3/year lower per one SD increase in ln-transformed FGF21 levels). Cross-sectionally, higher plasma FGF21 levels were significantly associated with higher pericardial fat volume, independent of traditional CVD risk factors and inflammatory markers. However, higher FGF21 levels tended to be associated with less pericardial fat accumulation over time. Nevertheless, such change in pericardial fat volume is very modest and could be due to measurement error. Further studies are needed to elucidate the longitudinal relationship of baseline FGF21 levels with pericardial fat accumulation.

Conflict of interest statement

The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. Lim S, Meigs JB. Ectopic fat and cardiometabolic and vascular risk. Int. J. Cardiol. 2013;169:166–176. doi: 10.1016/j.ijcard.2013.08.077. - DOI - PubMed
    1. Wu FZ, Wu CC, Kuo PL, Wu MT. Differential impacts of cardiac and abdominal ectopic fat deposits on cardiometabolic risk stratification. BMC Cardiovasc. Disord. 2016;22:16–20. - PMC - PubMed
    1. Ding J, et al. The association of pericardial fat with incident coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA) Am. J. Clin. Nutr. 2009;90:499–504. doi: 10.3945/ajcn.2008.27358. - DOI - PMC - PubMed
    1. Shah RV, et al. Pericardial, But Not Hepatic, Fat by CT Is Associated With CV Outcomes and Structure: The Multi-Ethnic Study of Atherosclerosis. JACC Cardiovasc. Imaging. 2017;10:1016–1027. doi: 10.1016/j.jcmg.2016.10.024. - DOI - PMC - PubMed
    1. Woo YC, Xu A, Wang Y, Lam KS. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin. Endocrinol. (Oxf.) 2013;78:489–496. doi: 10.1111/cen.12095. - DOI - PubMed

Grant support

Feedback